Helen Sabzevari

Helen Sabzevari

Chief Executive OfficeratPrecigen· In proxies 2021–2025

Pay in FY2025-1% from the year before · Precigen stock +273.2% the same year

Helen Sabzevari was paid $5.4M in FY2025 (Dec), down 1%. Precigen stock rose 273.2% that year.

Pay$100 in the stock at the end of FY20 → $41
Pay is from the Summary Compensation Table of each Precigen proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. PrecigenPublic company · 5 yr
    • Chief Executive Officer2021 – Present · 5 yrStock in role -39%
  2. Kinnate Biopharma Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • PrecigenDirector · 5 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?